Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Loncastuximab Tesirine and Acalabrutinib, Loncastuximab Tesirine, Loncastuximab tesirine, Loncastuximab tesirine and rituximab (Lonca-R)
Loncastuximab tesirine and rituximab · 1 trial · 1 indication
Maximum Tolerated Dose (MTD): MTD is defined as the highest dose under consideration that has an estimated DLT probability below 25% based upon the Bayesian optimal interval design. The MTD will be decided based on the BOIN decision rules set for phase 1a portion of the study.
| Arm | Type | Description |
|---|---|---|
| Treatment: All Patients | EXPERIMENTAL | This study has two main goals: Goal 1: The study will investigate the safety and tolerability of loncastuximab tesirine and rituximab (lonca-R). Goal 2: The study will determine the maximum tolerated dose of lonca-R. |
| Name | Type | Description |
|---|---|---|
| Loncastuximab tesirine and rituximab (Lonca-R) | DRUG | Patients will receive stereotactic radiosurgery (SRS) followed by a brain MRI approx. 3 weeks after SRS. This will be followed by loncastuximab tesirine and rituximab administered intravenously for a total of 6 cycles (every 21 days). |
Inclusion Criteria: * Participant aged ≥ 18 years * ECOG Performance Status ≤ 3 * Histologically confirmed primary CNS lymphoma or secondary diffuse large B-cell lymphoma (DLBCL) with CNS involvement with either: * Relapsed or refractory disease with at least 1 prior therapy OR * Ineligible fo...
Loncastuximab Tesirine is an investigational oncology drug being studied for post-transplant lymphoproliferative disorder, B-cell non-Hodgkin lymphoma, refractory diffuse large B-cell lymphoma, central nervous system lymphoma, and relapsed diffuse large B-cell lymphoma. It is in Phase 1 clinical development and is not FDA approved.
Loncastuximab Tesirine is developed by ADC Therapeutics SA, traded on the New York Stock Exchange under the ticker ADCT. The company is conducting clinical trials to evaluate the drug's safety and efficacy in various B-cell malignancies.
Loncastuximab Tesirine is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA. The drug is being studied in combination with other anti-cancer agents for relapsed or refractory B-cell non-Hodgkin lymphoma.
Loncastuximab Tesirine is being evaluated in several trials, including NCT03589469 (completed Phase 2 in relapsed/refractory DLBCL), NCT04970901 (recruiting Phase 1 LOTIS-7 in B-cell NHL), NCT06788964 (recruiting Phase 2 CORAL bridging therapy), and NCT07573436 (not yet recruiting Phase 1 PLUTO in post-transplant lymphoproliferative disorder).
Loncastuximab Tesirine is also known as Loncastuximab Tesirine and Acalabrutinib, Loncastuximab tesirine and rituximab (Lonca-R), and Loncastuximab tesirine and rituximab. These names refer to the drug in combination with other agents, while Loncastuximab Tesirine alone is the single-agent form.
Loncastuximab Tesirine is a small molecule oncology drug. The specific molecular target is not disclosed in the available information, but it is being studied in B-cell malignancies including diffuse large B-cell lymphoma and post-transplant lymphoproliferative disorder.